Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May;36(5):529-542.
doi: 10.1016/j.annonc.2024.12.015. Epub 2025 Jan 13.

The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study

E Rangelova  1 T F Stoop  2 T M E van Ramshorst  3 M Ali  4 E A van Bodegraven  5 A A Javed  6 D Hashimoto  7 E Steyerberg  8 A Banerjee  9 A Jain  10 A Sauvanet  11 A Serrablo  12 A Giani  13 A Giardino  14 A Zerbi  15 A Arshad  16 A G Wijma  17 A Coratti  18 A Zironda  19 A Socratous  20 A Rojas  21 A Halimi  22 A Ejaz  23 A Oba  24 B Y Patel  16 B Björnsson  25 B N Reames  26 B Tingstedt  27 B K P Goh  28 C Payá-Llorente  29 C D Del Pozo  29 C González-Abós  30 C Medin  31 C H J van Eijck  32 C de Ponthaud  33 C Takishita  34 C Schwabl  35 C Månsson  36 C Ricci  37 C A Thiels  19 D Douchi  38 D L Hughes  39 D Kilburn  40 D Flanking  41 D Kleive  42 D S Silva  43 B H Edil  10 E Pando  44 E Moltzer  45 E F Kauffman  46 E Warren  31 E Bozkurt  47 E Sparrelid  48 E Thoma  49 E Verkolf  32 F Ausania  50 F Giannone  51 F J Hüttner  49 F Burdio  52 F R Souche  53 F Berrevoet  54 F Daams  4 F Motoi  55 G Saliba  48 G Kazemier  4 G Roeyen  56 G Nappo  15 G Butturini  14 G Ferrari  13 G Kito Fusai  9 G Honda  57 G Sergeant  58 H Karteszi  59 H Takami  60 H Suto  61 I Matsumoto  62 I Mora-Oliver  63 I Frigerio  14 J M Fabre  53 J Chen  40 J G Sham  64 J Davide  43 J Urdzik  36 J de Martino  33 K Nielsen  65 K Okano  61 K Kamei  62 K Okada  66 K Tanaka  67 K J Labori  68 K E Goodsell  69 L Alberici  70 L Webber  71 L Kirkov  53 L de Franco  18 M Miyashita  72 M Maglione  73 M Gramellini  15 M Ramera  74 M J Amaral  75 M Ramaekers  76 M J Truty  19 M A van Dam  77 M W J Stommel  45 M Petrikowski  78 M Imamura  79 M Hayashi  60 M D'Hondt  80 M Brunner  81 M E Hogg  21 C Zhang  26 M Á Suárez-Muñoz  82 M D Luyer  76 M Unno  38 M Mizuma  38 M Janot  78 M A Sahakyan  83 N B Jamieson  84 O R Busch  5 O Bilge  47 O Belyaev  78 O Franklin  85 P Sánchez-Velázquez  52 P Pessaux  51 P S Holka  27 P Ghorbani  48 R Casadei  37 R Sartoris  86 R D Schulick  87 R Grützmann  83 R Sutcliffe  65 R Mata  44 R B Patel  23 R Takahashi  55 S Rodriguez Franco  87 S S Cabús  88 S Hirano  67 S Gaujoux  33 S Festen  89 S Kozono  34 S K Maithel  31 S M Chai  90 S Yamaki  7 S van Laarhoven  91 J S D Mieog  77 T Murakami  79 T Codjia  92 T Sumiyoshi  66 T M Karsten  89 T Nakamura  67 T Sugawara  93 U Boggi  46 V Hartman  56 V E de Meijer  17 W Bartholomä  94 W Kwon  95 Y X Koh  28 Y Cho  95 Y Takeyama  62 Y Inoue  72 Y Nagakawa  34 Y Kawamoto  57 Y Ome  57 Z Soonawalla  39 K Uemura  66 C L Wolfgang  96 J Y Jang  95 R Padbury  40 S Satoi  97 W Messersmith  98 J W Wilmink  99 M Abu Hilal  14 M G Besselink  5 M Del Chiaro  87 European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS)International Consortium on Advanced Pancreatic Surgery
Collaborators, Affiliations
Free article
Multicenter Study

The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study

E Rangelova et al. Ann Oncol. 2025 May.
Free article

Abstract

Background: Left-sided pancreatic cancer is associated with worse overall survival (OS) compared with right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with resectable pancreatic cancer (RPC), current randomized trials included mostly patients with right-sided RPC. The purpose of this study was to assess the association between neoadjuvant therapy and OS in patients with left-sided RPC compared with upfront surgery.

Patients and methods: This was an international multicenter retrospective study including consecutive patients after left-sided pancreatic resection for pathology-proven RPC, either after neoadjuvant therapy or upfront surgery in 76 centers from 18 countries on 4 continents (2013-2019). The primary endpoint was OS from diagnosis. Time-dependent Cox regression analysis was carried out to investigate the association of neoadjuvant therapy with OS, adjusting for confounders at the time of diagnosis. Adjusted OS probabilities were calculated.

Results: Overall, 2282 patients after left-sided pancreatic resection for RPC were included of whom 290 patients (13%) received neoadjuvant therapy. The most common neoadjuvant regimens were (m)FOLFIRINOX (38%) and gemcitabine-nab-paclitaxel (22%). After upfront surgery, 72% of patients received adjuvant chemotherapy, mostly a single-agent regimen (74%). Neoadjuvant therapy was associated with prolonged OS compared with upfront surgery (adjusted hazard ratio 0.69, 95% confidence interval 0.58-0.83) with an adjusted median OS of 53 versus 37 months (P = 0.0003) and adjusted 5-year OS rates of 47% versus 35% (P = 0.0001) compared with upfront surgery. Interaction analysis demonstrated a stronger effect of neoadjuvant therapy in patients with a larger tumor (Pinteraction = 0.003) and higher serum carbohydrate antigen 19-9 (CA19-9; Pinteraction = 0.005). In contrast, the effect of neoadjuvant therapy was not enhanced for splenic artery (Pinteraction = 0.43), splenic vein (Pinteraction = 0.30), retroperitoneal (Pinteraction = 0.84), and multivisceral (Pinteraction = 0.96) involvement.

Conclusions: Neoadjuvant therapy in patients with left-sided RPC was associated with improved OS compared with upfront surgery. The impact of neoadjuvant therapy increased with larger tumor size and higher serum CA19-9 at diagnosis. Randomized controlled trials on neoadjuvant therapy specifically in patients with left-sided RPC are needed.

Keywords: CA19-9; neoadjuvant therapy; pancreatic adenocarcinoma; pancreatic body/tail; resectable; tumor size.

PubMed Disclaimer

Similar articles

Publication types

MeSH terms

LinkOut - more resources